Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.5582/ddt.2020.03032 http://scihub22266oqcxt.onion/10.5582/ddt.2020.03032 32554953!ä!32554953 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32554953.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Drug+Discov+Ther 2020 ; 14 (3): 139-142 Nephropedia Template TP {{tp|p=32554953|t=2020. Can mesenchymal stem cell therapy be the interim management of COVID-19?|pdf=|usr=}}{{32554953}} gab.com Text Can mesenchymal stem cell therapy be the interim management of COVID-19 JO: Drug Discov Ther http://www.kidney.de/pget.php?&tw=1&pmid=32554953 #FOAvip COVID-19 pandemic has accounted for ~ 4.3 million confirmed cases and ~ 292,000 deaths (till 12(th) May, 2020) across the globe since its outbreak. Several anti-viral drugs such as RNA dependent RNA polymerase inhibitors (remdesivir, favipiravir, ribavirin), protease inhibitors (lopinavir, ritonavir) and drugs targeting endocytic pathway (hydroxychloroquine) are being evaluated for COVID-19 but standard therapeutics yet not available. Severe health deterioration in critically ill patients is characterized by pulmonary edema, severe respiratory distress, cytokine storm and septic shock. To combat cytokine storm, immune-therapy targeting IL-1, IL-2, IL-6 and TNFalpha are being evaluated and one of the promising immune-modulator is the mesenchymal stem cells (MSCs) that can surmount the severity of COVID-19 infections. Recent studies have shown that MSC-therapy significantly dampens the cytokine storm in critically ill COVID-19 patients. This communication endows with the insight of stem cell therapy and summarizes the recent studies on COVID-19 patients. Twit Text FOAVip Can mesenchymal stem cell therapy be the interim management of COVID-19 ????Drug Discov Ther http://www.kidney.de/pget.php?&tw=1&pmid=32554953 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32554953 #FOAvip English Wikipedia <ref>{{Cite pmid|32554953}}</ref> Can mesenchymal stem cell therapy be the interim management of COVID-19? #MMPMID32554953 Bamba C; Singh SP; Choudhury S Drug Discov Ther 2020[Jul]; 14 (3): 139-142 PMID32554953show ga COVID-19 pandemic has accounted for ~ 4.3 million confirmed cases and ~ 292,000 deaths (till 12(th) May, 2020) across the globe since its outbreak. Several anti-viral drugs such as RNA dependent RNA polymerase inhibitors (remdesivir, favipiravir, ribavirin), protease inhibitors (lopinavir, ritonavir) and drugs targeting endocytic pathway (hydroxychloroquine) are being evaluated for COVID-19 but standard therapeutics yet not available. Severe health deterioration in critically ill patients is characterized by pulmonary edema, severe respiratory distress, cytokine storm and septic shock. To combat cytokine storm, immune-therapy targeting IL-1, IL-2, IL-6 and TNFalpha are being evaluated and one of the promising immune-modulator is the mesenchymal stem cells (MSCs) that can surmount the severity of COVID-19 infections. Recent studies have shown that MSC-therapy significantly dampens the cytokine storm in critically ill COVID-19 patients. This communication endows with the insight of stem cell therapy and summarizes the recent studies on COVID-19 patients. |*Betacoronavirus[MESH] |*Disease Management[MESH] |Antiviral Agents/administration & dosage[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Clinical Trials as Topic/methods[MESH] |Coronavirus Infections/blood/diagnosis/drug therapy/*therapy[MESH] |Cytokines/antagonists & inhibitors/blood[MESH] |Humans[MESH] |Mesenchymal Stem Cell Transplantation/*methods/trends[MESH] |Pandemics[MESH] |Pneumonia, Viral/blood/diagnosis/*therapy[MESH]Can mesenchymal stem cell therapy be the interim management of COVID-1(epmc).pdf DeepDyve Pubget Overpricing